Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist

Circulation

Volumn 89, Issue 1, 1994, Pages 3-12

  Mousa, Shaker A ^a   Bozarth, Jeffery M ^a   Forsythe, Mark S ^a   Jackson, Sharon M ^a   Leamy, Andrew ^a   Diemer, Mark M ^a   Kapil, Ram P ^a   Knabb, Robert M ^a   Mayo, Michael C ^a   Pierce, Sandra K ^a   De Grado, William F ^a   Thoolen, Martin J ^a   Reilly, Thomas M ^a  

^a DUPONT COMPANY   (United States)

Author keywords

antiplatelet agents; antithrombotic agents; DMP 728; glycoproteins; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; FIBRINOGEN; FIBRINOGEN RECEPTOR; PLASMA PROTEIN; SODIUM CHLORIDE; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RABBIT; RAT; THORACIC AORTA; THROMBOCYTE AGGREGATION;

EID: 0027957884     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.89.1.3     Document Type: Article

References (32)

1. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:585-691.
2. Rubenstein MD, Wall RT, Bain DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J. 1981;102:363-367.
3. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol. 1981;48: 395-402.
4. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
5. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 1985;5:175B-184B.
6. Travis J. Biotech gets a grip on cell adhesion: frontier in biotechnology. Science. 1993;260:906-908.
7. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
8. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
9. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Weber W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol. 1987;10: 998-1004.
10. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Platelet Health Dis. 1990;4:1-26.
11. Saltiel E, Ward A, Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs. 1987;34:222-262.
12. 2 and serotonin after thrombolysis with t-PA in a canine preparation of coronary thrombosis. Circulation. 1988;77:678-684.
13. Walenga JM, Pifarra R, Fareed J. Recombinant hirudin as an antithrombotic agent. Drugs Future. 1990;15:267-270.
14. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
15. John JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1988;78:546-556.
16. Pytele R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science. 1986;231:1559-1562.
17. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell. 1991;65:359-362.
18. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its a subunit. J Biol Chem. 1990;265:3440-3446.
19. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986; 68:783-786.
20. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa, in patient with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
21. Ruggeri ZM, Houghton RA, Russel SR, Zimmerman TS. Inhibition of platelet function with synthetic peptide designed to be high affinity antagonist of fibrinogen binding to platelets. Proc Natl Acad Sci U S A. 1986;83:5708-5712.
22. Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent. Thromb Res. 1991;62: 567-578.
23. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci. 1992;13:413-417.
24. Shebuski RJ, Berry DE, Bennett DB, Romoff T, Storer BL, Ali F, Samanen J. Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost. 1989;61:183-188.
25. Bennett JS, Valaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393-1401.
26. Folts JD. Experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance. Cardiovasc Rev Rep. 1982;3:370-382.
27. Folts JD, Gallagher K, Rowe GG. Blood flow reduction in stenosed coronary arteries: vasospasm or platelet aggregation? Circulation. 1982;65:248-255.
28. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17: 841-853.
29. 2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation. 1990;81:617-627.
30. Mousa SA, Mayo MC, Bozarth JM, Forsythe MS, Reilly TM. Antiplatelet effects of thrombin inhibitors versus GPIIb/IIIa receptor antagonists: comparative kinetic and mechanistic analysis. Thromb Haemost. 1993;69:2792. Abstract.
31. Mousa SA, Bozarth JM, Forsythe MS, Lorelli W, Ramachandran N, Jackson S, De Grado W, Reilly TM. Antiplatelet efficacy and specificity of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Cardiology. In press.
32. Mousa SA, De Grado WF, Jackson S, Thoolen MJ, Pierce SK, Bozarth JM, Hassell S, Reilly TM. Antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. Circulation. 1993;88:I-319, 1706. Abstract.